Clinical Consultant, Aspen Pharma, the Netherlands.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620977702. doi: 10.1177/1076029620977702.
The SARS-CoV-2 pandemic has focused attention on prevention, restriction and treatment methods that are acceptable worldwide. This means that they should be simple and inexpensive. This review examines the possible role of glycosaminoglycan (GAG) antithrombotics in the treatment of COVID-19. The pathophysiology of this disease reveals a complex interplay between the hemostatic and immune systems that can be readily disrupted by SARS-CoV-2. Some of the GAG antithrombotics also possess immune-modulatory actions and since they are relatively inexpensive they could play an important role in the management of COVID-19 and its complications.
SARS-CoV-2 大流行引起了对全球范围内可接受的预防、限制和治疗方法的关注。这意味着这些方法应该简单且廉价。本综述探讨了糖胺聚糖（GAG）抗血栓形成药物在 COVID-19 治疗中的可能作用。该疾病的病理生理学揭示了止血和免疫系统之间复杂的相互作用，这种相互作用很容易被 SARS-CoV-2 破坏。一些 GAG 抗血栓形成药物还具有免疫调节作用，而且由于它们相对廉价，因此在 COVID-19 及其并发症的管理中可能发挥重要作用。
